Humoral and Cellular Immune Response on COVID-19 Patients and Sinovac Vaccine Participants
DOI:
https://doi.org/10.24293/ijcpml.v30i2.2061Keywords:
Vaccine, anti-SARS-CoV-2, CD8+Abstract
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 is a new SARS-CoV virus. A person who is infected with this virus will induce both humoral and cellular immune responses. Herd immunity can be achieved through vaccination. The purpose of vaccination is the formation of antibodies capable of neutralizing coronavirus against the receptor binding domain. This study aimed to determine the differences between humoral and cellular immune responses between confirmed COVID-19 patients and Sinovac vaccine participants. This observational analytic study with a prospective cohort approach was conducted between March to October 2021. Fifty subjects (25 officers who had received vaccinations for COVID-19 patients and 25 COVID-19 patients treated at the Dr. Moewardi General Hospital) and met the inclusion and exclusion criteria were enrolled. Different tests were carried out to see the difference between the levels of CD8+ T cells and anti-SARS-CoV-2 antibodies in the vaccine group and the COVID-19 patient group. There was no significant difference in humoral immune response (anti-SARS-CoV-2) between the vaccine group and COVID-19 patient group [33.93 (0.4–196.6) U/L vs. 101.28±158.59 U/L; p=0.409], but there was a significant difference in cellular immune response (CD8+) between the vaccine group and COVID-19 patient group [878.52±47368 cells/µL vs. 270.16±213.64 cells/µL; p=0.001]. CD8 assay can be used as a parameter to differentiate the cellular immune response between COVID-19 patients and COVID-19 vaccine recipients.
Downloads
References
Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, et al. Coronavirus Disease 2019 (COVID-19): A perspective from China. Radiology, 2020; 296(2): E15–E25.
Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. International Journal of Infectious Diseases, 2020; 101: 138–148.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 2020; 10(5): 766-788.
Chen Z, Wherry EJ. T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020; 20: S29-S36.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrier T, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020; 181: 271–280.
Liu L, Xu L, Lin C. T cell response in patients with COVID-19. Blood Science, 2021; 2: 76-78.
Liu Z, Long W, Tu M, Chen S, Huang Y, et al. Lymphocyte subset (CD4+ - CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect, 2020; 81(2): 318-356.
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis, 2020; 221 (11): 1762–9.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2020; S1473–3099(20): 30843–4.
Knight EK. A safe & effective vaccine for COVID-19: Opportunities, challenges and an equity imperative. 2020. Available from: sites.udel.edu/healthycommunities. 302.831.0683 (accessed March 10, 2021).
World Health Organization (WHO). 2020. Update on COVID-19 vaccines & immune response. Available from: https://www.who.int/docs/default-source/coronaviruse/ risk-comms-updates/update52_vaccines.pdf?sfvrsn=b11be994_4 (accessed April 5, 2021).
Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021; 372(6549): 1418-1423.
Wang F, Nie J, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases, 2020; XX (XX XXXX): 1–8.
Speiser DE, Bachmann ME. COVID-19: Mechanisms of vaccination and immunity. Vaccine, 2020; 8(404): 1-19.
Rha MS, Shin EC. Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cellular & Molecular Immunology, 2012; 18: 2325–2333.
Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Review Immunology, 2021; 21: 475-484.
Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, et al. SARS-CoV-2 (COVID-19) vaccines structure, mechanisms, and effectiveness: A review. International Journal of Biological Macromolecules, 2021; 188: 740–750.
Risamasu JD, Suparyatmo JB, Kurniati A. Diagnostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio for COVID-19 screening. IJCPML, 2023; 30(1): 33-38.
Tan W, Lu Y, Zhang J, Wang J, Yunjie DY, et al. Viral kinetics and antibody responses in patients with COVID-19. MedRxiv, 2020; 2020.03.24.20042382.
Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med, 2020; 6: 217(1): e20190418.
Bellesi S, Metafuni E, Hohaus S, Maiolo E, Marchionni F, et al. Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. Br. J. Haematol, 2020; 191: 207e211.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp. Med, 2020; 8: 420-22.
Tartaro DL, Paolini A, Mattioli M, Swatler J, Neroni A, et al. Detailed characterization of SARS-CoV 2 specific T and B cells after infection or heterologous vaccination. Frontier Immunology, 2023; 14: 1123724.
Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLos One, 2021; 16(1): e0245532.
Zhang Y, Xu J, Jia R, Yi C, Gu W, et al. Protective humoral immunity in SARS-CoV-2 infected pediatric patients. Cell Mol Immunol, 2020; 17: 2–4.
Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 2020; 181: 1489e1501.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant Spike protein nanoparticle vaccine. N Engl J Med, 2020; 383(24): 2320–32.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
